Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 4
2004 10
2005 8
2006 12
2007 20
2008 16
2009 27
2010 15
2011 14
2012 26
2013 22
2014 18
2015 14
2016 34
2017 19
2018 32
2019 29
2020 19
2021 7
2022 5
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

335 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: a Swedish national population-based register study.
Linder M, Ekbom A, Brobert G, Vogtländer K, Balabanova Y, Becattini C, Carrier M, Cohen AT, Coleman CI, Khorana AA, Lee AYY, Psaroudakis G, Abdelgawwad K, Rivera M, Schaefer B, Giunta DH. Linder M, et al. Among authors: coleman ci. J Thromb Thrombolysis. 2024 May 12. doi: 10.1007/s11239-024-02992-1. Online ahead of print. J Thromb Thrombolysis. 2024. PMID: 38735015
Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low-Molecular-Weight Heparin: The OSCAR-UK Study.
Cohen AT, Wallenhorst C, Rivera M, Ay C, Schaefer B, Abdelgawwad K, Psaroudakis G, Brobert G, Ekbom A, Lee AYY, Khorana AA, Becattini C, Carrier M, Coleman CI, Martinez C. Cohen AT, et al. Among authors: coleman ci. Thromb Haemost. 2024 Apr 8. doi: 10.1055/a-2259-0662. Online ahead of print. Thromb Haemost. 2024. PMID: 38301711 Free article.
Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study.
Dobesh PP, Fermann GJ, Christoph MJ, Koch B, Lesén E, Chen H, Lovelace B, Dettling T, Danese M, Ulloa J, Danese S, Coleman CI. Dobesh PP, et al. Among authors: coleman ci. Res Pract Thromb Haemost. 2023 Aug 30;7(6):102192. doi: 10.1016/j.rpth.2023.102192. eCollection 2023 Aug. Res Pract Thromb Haemost. 2023. PMID: 37753225 Free PMC article.
Comparative outcomes associated with rivaroxaban versus warfarin use in elderly patients with atrial fibrillation or acute venous thromboembolism managed in the United States: a systematic review of observational studies.
Baker WL, Roberts MS, Bessada Y, Caroti KS, Ashton V, Bookhart BK, Coleman CI. Baker WL, et al. Among authors: coleman ci. Curr Med Res Opin. 2023 Sep;39(9):1183-1194. doi: 10.1080/03007995.2023.2247988. Epub 2023 Aug 24. Curr Med Res Opin. 2023. PMID: 37584187
Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program.
Caroti KS, Khorana AA, Becattini C, Lee AYY, Ekbom A, Carrier M, Cohen AT, Brescia C, Abdelgawwad K, Psaroudakis G, Rivera M, Schaefer B, Brobert G, Coleman CI. Caroti KS, et al. Among authors: coleman ci. Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231189282. doi: 10.1177/10760296231189282. Clin Appl Thromb Hemost. 2023. PMID: 37583314 Free PMC article.
Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding.
Caroti KS, Becattini C, Carrier M, Cohen AT, Ekbom A, Khorana AA, Lee AYY, Brescia C, Abdelgawwad K, Psaroudakis G, Rivera M, Schaefer B, Brobert G, Coleman CI. Caroti KS, et al. Among authors: coleman ci. TH Open. 2023 Jul 10;7(3):e206-e216. doi: 10.1055/s-0043-1770783. eCollection 2023 Jul. TH Open. 2023. PMID: 37435565 Free PMC article.
Clinical and health care resource use burden of hospitalizations for oral factor Xa inhibitor-associated major bleeding: A real-world analysis of Medicare beneficiaries.
Williams JM, Lovelace B, Christoph MJ, Li S, Guo H, Hoover M, Coleman CI. Williams JM, et al. Among authors: coleman ci. J Am Coll Emerg Physicians Open. 2023 May 22;4(3):e12956. doi: 10.1002/emp2.12956. eCollection 2023 Jun. J Am Coll Emerg Physicians Open. 2023. PMID: 37223213 Free PMC article.
Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism.
Coleman CI, Caroti KS, Abdelgawwad K, Psaroudakis G, Fatoba S, Rivera M, Schaefer B, Brobert G, Khorana AA, Becattini C, Lee AYY, Ekbom A, Carrier M, Brescia C, Cohen AT. Coleman CI, et al. JACC CardioOncol. 2023 Feb 7;5(2):189-200. doi: 10.1016/j.jaccao.2022.10.014. eCollection 2023 Apr. JACC CardioOncol. 2023. PMID: 37144109 Free PMC article.
335 results